Development and evaluation of Keratin 7/19 serum test for ovarian cancer in combination with biomarkers CA125 and HE4

Examensarbete för masterexamen

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12380/205444
Download file(s):
There are no files associated with this item.
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLevin, Olle
dc.contributor.departmentChalmers tekniska högskola / Institutionen för kemi- och biotekniksv
dc.contributor.departmentChalmers University of Technology / Department of Chemical and Biological Engineeringen
dc.date.accessioned2019-07-03T13:34:33Z-
dc.date.available2019-07-03T13:34:33Z-
dc.date.issued2014
dc.identifier.urihttps://hdl.handle.net/20.500.12380/205444-
dc.description.abstractOvarian neoplasms are one of the most common pathologies among women of all age groups. It has been estimated that up to 10% of all women in the United States will undergo a surgical procedure owing to a suspected ovarian mass during their lifetime, and around a fifth of these women will suffer from malignancy. Early detection of ovarian cancer is crucial for successful treatment and survival. The aim of this master thesis was to develop a Keratin 7/19 serum test for ovarian cancer which in combination with already established biomarkers CA125 and HE4 could increase the sensitivity of cancer detection while maintaining high specificity. Different antibody combinations directed against keratin 7/19 were evaluated as possible candidates for an ovarian cancer serum test based on a “sandwich” type enzyme immunoassay. The combination K7A/K19A showed promising results and was optimized as a keratin7/19 serum test with sufficient technical performance allowing clinical valuation on patient serum samples. The clinical evaluation showed that the test exhibited a surprisingly high specificity and a high discrimination power in distinguishing between benign disease and cancer. Only low concentrations of keratin 7/19 were detected in both benign disease samples and blood donor samples. The test exhibited high sensitivity for ovarian cancer and could possibly be used as a complement to the already established tumor markers CA125 and HE4. However, further evaluation is needed on a larger ovarian cancer population with clear classified tumor grade and stage. Analysis of other types of cancers and benign diseases indicate that additional clinical applications may exist for the test. Obtained results encourage for further studies in bladder cancer.
dc.language.isoeng
dc.setspec.uppsokPhysicsChemistryMaths
dc.subjectLivsvetenskaper
dc.subjectBioinformatik och systembiologi
dc.subjectMedicinsk bioteknik
dc.subjectMedicinsk bioteknologi
dc.subjectLife Science
dc.subjectBioinformatics and Systems Biology
dc.subjectMedical Biotechnology
dc.subjectMedical Biotechnology
dc.titleDevelopment and evaluation of Keratin 7/19 serum test for ovarian cancer in combination with biomarkers CA125 and HE4
dc.type.degreeExamensarbete för masterexamensv
dc.type.degreeMaster Thesisen
dc.type.uppsokH
Collection:Examensarbeten för masterexamen // Master Theses



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.